Alzheimer’s in the U.S.
Alzheimer’s 2100
Alzheimer’s drug market
SYMPTOM PREVENTIVE
0
Multiple attempts
Alzheimer's Drug From Pfizer, J&J Fails in Late-Stage Trial
Lilly Halts Alzheimer's Drug Trial
Glaxo’s Avandia Fails to Benefit Alzheimer’s Patients
$10B
PREVENTIVEDRUG MARKET
$1B
FAILED DRUGS
The best time to treat Alzheimer’s
Disease is likely to be before
memory loss and tissue
destruction occurs…
NORMAL BRAIN ALZHEIMER’S
Alter the trajectory
disease progressio
n
time
Current standard of diagnosis
Preventive
3 years
Our technology
EYETRACKING
NEWIMAGE
CHANGEDETECTION
3YEARS
EARLIER
Alzheimer’s conversion
0 100
0%of high scorers
99.9%of low scorers
20,000requiredpatients
100new clinical
trials each year
1Phase IV
approved therapy
Strategy
the Alzheimer’s diagnostic
Patents filed and pending
Worldwide license
Pilot discussions
today
Team
Elli KaplanCEO
Colin McDonaldCMO
Dr. Stuart Zola
Dr. Beth Buffalo
Dr. Eugene Agichtein
Scientific Advisory
Next steps
Business development
Seed capital